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Summary 
A large panel of CD8 + T  cell clones generated from peripheral blood lymphocytes (PBL)  of 
healthy donors or human immunodeficiency virus (HIV)-infected individuals were assessed for 
both cytokine secretion profile and CD30 expression and release. The great majority of CD8 + 
T cell dones generated from healthy individuals showed the ability to produce interferon 3' (IFN-3'), 
but not interleukin 4  (IL-4), and none of them either expressed membrane CD30 or released 
substantial amounts of soluble CD30 (sCD30) in their supernatant. In contrast, high numbers 
of CD8 + T cell clones generated from HIV-infected individuals,  which produced IL-4 (and IL-5) 
in addition to IFN-3' or IL-4 (and IL-5) alone, expressed membrane CD30 and released detectable 
amounts of sCD30 in their supernatants.  Indeed, CD30 expression appeared to be positively 
correlated with the ability of CD8 + T cell clones to produce IL-4 and IL-5 and inversely cor- 
related with their ability to produce IFN-% whereas no correlation between CD30 expression 
and production of IL-10 was observed. These data suggest that CD30 is a marker for CD8 + 
T  cells that have switched to the production of type 2 helper cytokines. 
C 
D30 is a 120-kD surface antigen originally identified by 
the Ki-1 mAb developed against Hodgkin s and Reed- 
Sternberg (H-RS) cells  (1).  CD30  antigen expression was 
then found in various non-Hodgkin's lymphomas (2), as well 
as on several virally transformed T-  (HTLV I  and II) and 
B- (EBV) cell lines (3, 4). That CD30 plays a role in normal 
lymphoid interaction is suggested by its histological detec- 
tion on a scanty population of lymphoid cells in reactive lymph 
nodes and by induced expression on purified T  and B cells 
after lectin activation (5). cDNA cloning studies demonstrated 
that CD30 belongs to the TNF/nerve growth factor (NGF) 
receptor family (6, 7), whose ligand is a new membrane-bound 
cytokine sharing a number of structural and functional similar- 
ities with TNF (8). At present, the physiological role of CD30 
is unknown. In recent studies, however, we have demonstrated 
that CD30 is selectively expressed by human CD4 + T cells 
producing type 2 helper (Th2) cytokines (9). 
In this report we have asked whether the association be- 
tween CD30 expression and the ability to produce Th2-type 
cytokines is restricted to the CD4 § T cell subset or also ex- 
tends to CD8 + T lymphocytes. To answer this question we 
have analyzed large panels of CD8 + T cell clones generated 
from  both  normal  donors  and  HIV-infected individuals. 
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CD8 + T  cell clones producing Th2-type cytokines, which 
are rare in normal subjects,  can be indeed generated in large 
numbers from some HIV-infected individuals (10). Results 
showed that CD8 + T cell clones producing IFN-3/but not 
IL-4 or IL-5 (Thl-like) neither expressed membrane CD30 
nor released soluble CD30 (sCD30) in their supematants (SN), 
whereas both membrane CD30 and sCD30 are consistently 
found in human CD8 + T  cells producing IL-4 and IL-5 
(Th0- or Th2-1ike).  Thus,  CD30 expression appears  to be 
a marker not only for CD4 § Th2 cells, but also CD8 + T 
cells  that  have  switched  to  the  production  of Th2-type 
cytokines. 
Materials  and Methods 
Patients.  The study was performed in five HIV-l-infected pa- 
tients and three HIV-l-seronegative healthy volunteers. According 
to the Centers for Disease Control (CDC) criteria (11), three of 
the patients were classified  in the Group IV Subgroup C-1 because 
two have suffered  from Pneumoffstis carinii and one from ToxopIasma 
gondii infection; two in the Group IV Subgroup D (one with Ka- 
posi's sarcoma and  one with  non-Hodgkin's  lymphoma).  Im- 
munophenotyping of PBMC by flow cytometry  revealed  very low 
levels of CD4 + T cells (<50/#1) in all five HIV-l-infected patients 
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840,  and  1,100 cells/#l,  respectively).  Absolute values of CD8 § 
T cells were within normal values (ranging from 350 to 600 cells/#l) 
in both HIV-l-infected patients and healthy subjects.  All patients 
and controls gave informed consent for the studies. 
Reagents.  PHA was purchased from GIBCO BRL (Gaithers- 
burg, MD) and PMA from Sigma Chemical Co. (St. louis, MO). 
Recombinant  ID2 was a kind  gift of Eurocetus  (Milan,  Italy). 
Recombinant Ib5 and Ibl0 were purchased from Amersham In- 
ternational (Amersliam, Bucks, UK) and Genzyme Corp. (Cam- 
bridge, MA), respectively.  Anti-CD3, anti-CD4, anti-CD8, anti- 
od[$-TCK mAbs were purchased from Becton Dickinson & Co. 
(Mountain View, CA). Anti-CD30 mAb (Ber-H2) was purchased 
by Dako (Glostrup, Denmark). 
T  Cell Cloning System.  PBMC were obtained from the four 
HIV-l-infected patients  and  the  two  HIV-seronegative healthy 
volunteers after Ficoll-Hypaque gradient centrifugation, and T cells 
cloned according to a previously described technique that allows 
the clonal expansion of virtually every T cell regardless  of its an- 
tigen specificity  (10). Briefly, PBMC were seeded under limiting 
dilution conditions (0.3 cells/well)  in round-bottomed microwells 
containing l0  s irradiated  allogeneic spleen cells (as feeder cells) and 
PHA (1% vol/vol) in a final volume of 0.2 ml RPMI 1640 medium 
supplemented with 2 mM t-glutamine, 2  x  10 -5 M 2-ME (com- 
plete medium) containing human recombinant II~2 (20 U/ml) and 
10%  FCS (Hyclone Laboratories, Logan, UT).  Growing micro- 
cultures  were then  supplemented  at weekly intervals with  IL-2 
(20 U/ml) and 10  s irradiated feeder cells. 
Immunophenotyping ofT Cell Clones.  Cell surface marker anal- 
ysis of T cell clones was performed on a Cytoron Absolute cyto- 
fluorimeter (Ortho Pharmaceuticals, Raritan,  NJ) by using fluo- 
resceinated (FITC) or phycoerythrinated (PE) anti-CD3, anti-CD4, 
anti-CDS,  anti-cff~-TCK, or anti-CD30,  as described (9,  10). 
Assessment of Cytokine Secretion Profile of T  Cell Clones.  The 
cytokine  secretion  profile  of  T  cell  clones  was  evaluated  by 
stimulating  106 T  cell blasts from each  done in  1 ml complete 
medium with PMA plus anti-CD3 Ab, as reported elsewhere (10). 
After 24 h, culture supematants were collected and stored at - 70~ 
until used.  The determination of IFN-3, and Ib4 was performed 
by a commercial KIA (Centocor Inc., Malvern, PA) and a com- 
mercial ELISA (Quantikine;  K & D  Systems,  Inc., Minneapolis, 
MN), respectively. ID5 and I1,-10  were quantified by in house-made 
capture  ELISAs  using  anti-Ib5  or  anti-Ibl0  mAb  bound  to 
microwell plates, and biotinylated anti-IL-5 or anti-Ibl0 mAbs (Phar- 
Mingen, San Diego, CA) as revealing  antibodies, respectively.  T 
cell clone SN showing IFN-',/, ID4, Ib5, or IL-10 levels 5 SD over 
the mean levels in control SN derived from irradiated feeder cells 
alone were regarded as positive. 
Assessment of sCD30,  sCD30  was  measured  in  the  SN  of 
CD8 § T cell clones stimulated for 24 h with PMA plus anti-CD3 
mAb by a CD30 ELISA test kit (Dakopatts, Glostrup, Denmark), 
based on the use of two mAbs reacting with two different epitopes 
of the 88-kD soluble form of CD30 molecule. The standard curve 
was prepared from six sCD30 calibrators and the concentration 
of sCD30 in SN was determined by interpolation of values detected 
in duplicate samples. The detection limit of the assay was estimated 
to be 1 U/ml by determination of the mean absorbanee (-+ 2 SD) 
of 20  measurements of the 0 U/ml standard  (12). 
Table  1.  Cytokine Production Profile of CD8 + T  Cell Clones Generated  from Peripheral Blood of HIV-seronegative 
and HIV-seropositive Individuals 
No.  of clones  showing  the indicated profile 
No.  of CD8 + 
Subjects  clones tested  Thl-like  Th0-1ike  Th2-1ike 
HIV-seropositive 
SC  21  2  9  10 
GC  19  15  1  3 
AM  54  24  18  12 
SK  112  36  55  21 
TM  37  28  4  5 
Total clones  243  105  (43%)*  87  (36%)*  51  (21%) S 
HIV-seronegative 
pp  84  70  14  0 
MA  39  38  1  0 
AM  21  14  7  0 
All clones  144  122  (85%)*  22  (15%)*  0 
CD8 + T cell clones were stimulated for 24 h with PMA plus anti-CD3 Ab and assessed for the ability to produce IL-4 and IFN-'r in their superna- 
rants as described in Materials and Methods. Clones producing IFN-% but not [L-4, were classified as Thl-like, clones producing both IFN-y and 
IL-4 were classified as Th0-1ike, and clones producing IL-4, but not IFN-% were dassified as Th2-1ike. 
* p <0.0005. 
*  p <0.00O5. 
s p <0.0005. 
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Figure  1.  Expression  of membrane CD30 by four representative Thl-like (PP.20, PP.11, SR..68, and SC.14) four representative Th0-1ike (SC.37, 
SR.102, SR.42, and SC.117), and four representative Th2-1ike (SP,.19, SR.35, SC.19, and SR.22) CD8 + T cell clones. T cell blasts from each clone 
were stained with the FITC-conjugated anti-CD30 mAb, and membrane CD30 expression was determined by flow cytometry. Values indicate the 
percentage of positive T blasts from each clone. 
Results 
A total number of 144 CD8 §  odB-TCR + T  cell clones 
generated from three normal donors and of 243 CD8 + c~/3- 
TCR + T cell clones generated from five HIV-infected indi- 
viduals were assessed  for ability to produce IFN-3r and/or 
IL-4 in response to stimulation  with PMA plus anti-CD3 
mAb.  As shown in Table 1,  85%  of CD8 + T  cell clones 
generated from normal donors produced IFN-3/but not IL-4 
(Thl-like), whereas the other 15% produced both IFN-3' and 
IL-4  (Th0-1ike).  In  contrast,  only  43%  of CD8 +  T  cell 
clones generated from HIV-infected individuals  showed a Thl- 
like profile, whereas 36% produced IL-4 in addition to IFN-y 
(Th0-1ike) and 21% produced IL-4 but not IFN-3' (Th2-1ike). 
A number of randomly selected CD8 + T cell clones from 
both normal donors and HIV-infected individuals were then 
assessed for membrane CD30 expression (112 T  cell clones) 
and sCD30 release (84 T  cell clones). Thl-like CD8 + T cell 
clones showed low or undetectable expression of membrane 
CD30 and did not release sCD30, whereas CD30 expression 
was  found  in  virtually  all  Th2-1ike  CD8 +  T  cell clones. 
Th0-1ike CD8 + T  cell clones showed an intermediate pat- 
tern  of CD30  expression  (Figs.  1 and  2).  Likewise,  high 
proportions of both Th2- and Th0-1ike clones also produced 
substantial amounts of sCD30 in their supernatants (Fig. 2). 
As shown in Fig.  3,  CD30 expression was positively cor- 
related with the ability of CD8 + T  cell clones to produce 
IL-4 and IL-5 and inversely correlated with their ability to 
produce IFN-% whereas no correlation between the expres- 
sion of CD30 and the ability of CD8 §  clones to produce 
IL-10 was observed. 
Discussion 
In a recent study, we have shown that CD30, a member 
of the TNF receptor superfamily (6, 7) is selectively expressed 
by human CD4 + T cells producing Th2-type cytokines (9). 
Here, we demonstrate that even on activated CD8 + T  cells 
CD30 is selectively expressed by those producing Th2-type 
cytokines. In fact, we found an inverse correlation of CD30 
expression with the production of IFN-~/and positive corre- 
lation with the production  of IL-4 and IL-5 even on acti- 
vated  CD8 +  T  cells.  No  correlation  was  found  between 
CD30 expression and production of IL-IO by CD8 + T  cell 
clones. This finding is not surprising since IL-10 production 
in humans is not restricted to Th2 cells (13,  14),  as it is in 
the mouse (15). Thus, these data strongly support the view 
that the expression of CD30 reflects and/or defines a selec- 
tive differentiation and/or activation pathway of T cells (both 
CD4 + and CD8 §  producing  Th2-type cytokines.  So far, 
however, the molecular mechanisms responsible for this as- 
sociation remain  unclear. 
We have previously demonstrated the presence of Th2-1ike 
CD8 + T  cells  showing B cell helper  activity and reduced 
cytolytic potential in two HIV-infected patients with a Job's- 
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like syndrome (10). The results here reported support this 
finding and suggest that the switch of CD8 + T cells is not 
limited to a few patients suffering from Job's-like syndrome 
but may occur, even if to lower extent, in higher proportions 
of HIV-infected individuals. At present, however, the reason 
why so high numbers of CD8 + T cells in HIV-infected in- 
dividuals differentiate in vitro into clones showing a Th2- 
type profile of cytokine production is unclear. 
Recently, it has been shown that serum levels of sCD30 
are elevated in the large majority of HIV-infected individuals 
and represent an indicator of progression to AIDS indepen- 
Figure  2.  Expression of membrane CD30 (top) and production of soluble 
CD30 (bottom) by CD8 + T cell clones with established Thl-, Th0-, or 
Th2-1ike profile of cytokine  secretion.  CD8 + T cell clones were gener- 
ated from PBMC of HIV-seronegative healthy donors (O) or HIV-infected 
individuals (O), as described in Materials and Methods,  and assessed for 
their cytokine secretion profile by 24-h stimulation  with PMA plus anti- 
CD3 mAb. Clones producing IFN-~/but not I1.-4 were classified as Thl- 
like, clones producing  both IFN-3~ and II.-4 were classified as Th0-1ike, 
and clones producing IL-4  but not IFN-"/were classified  as Th2-1ike. Mem- 
brane CD30 expression was evaluated by flow cytometry on CD8 + T cell 
clones on day 7 after the last stimulation  when they were growing in the 
presence of IL-2 alone, sCD30 production was assessed by a CD30 ELISA 
kit assay in culture SN of the same clones after  24-h  stimulation  with 
PMA plus anti-CD3 mAb. 
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Figure  3.  Correlation between 
membrane  CD30  expression  and 
production of different cytokines by 
CD8 + T cell clones generated from 
HIV-seronegative  healthy  donors 
(O)  or  HIV-infected  individuals 
(O). Membrane  CD30 expression 
was  assessed as  described  in  the 
legend  of Fig.  1.  Production  of 
IFN-%  Ib4,  II.,5,  and  lbl0  was 
evaluated in the SN ofT cell clones 
after 24-h stimulation  with PMA 
plus anti-CD3 mAb by appropriate 
ELISA, as described in Materials and 
Methods. dent of other prognostic parameters (12). The present demon- 
stration of high numbers of CD8 + Th2-1ike clones that ex- 
press  membrane CD30 and can release  detectable amounts 
of sCD30  may provide a  reasonable explanation for  this 
finding. Whether elevated serum levels of sCD30 in HIV 
infection reflect cleavage  of membrane CD30 on activated 
Th2-1ike (CD4 § and CD8 +) T and/or B cells or result from 
HIV-mediated apoptosis of both CD4 § and CD8 § T  cells 
remains to be established. Whatever mechanism is the pos- 
sible role of CD30 in the immunopathogenesis of HIV in- 
fection deserves  further investigation. 
We thank Lorella Morosato for her excellent technical assistance. 
This work was supported by grants from Associazione Italiana Ricerca Cancro, Ministero ddla Sanit~ 
(Progetto AIDS), and Consiglio Nazionale Ricerche (Target Projects "Biotechnologies and Bioinstrumen- 
tations"  and "Clinica Application of Research in Oncology"). 
Address correspondence to Dr. Sergio Romagnani, Istituto di Clinica Medica 3, Viale Morgagni, 85, 50134 
Florence, Italy. 
Received for publication  2 August  1994. 
R~l'~nces 
1.  Schwab, U., H. Stein, J. Gerdes, H. Lemke, H. Kirchner, M. 
Schaadt and  V.  Diehl.  1982. Production  of a monoclonal 
antibody specific for Hodgkin and  Steruberg-Reed cells of 
Hodgkin's disease and a subset of normal lymphoid cells. Na- 
lure (Lond.). 299:65. 
2.  Stein,  H., D.Y. Mason, J. Gerdes, N. O'Connor, J. Wainscoat, 
G. Pellesen, K. Gatter, B. Falini, G. Delsol, H. Lemke, et al. 
1985. The expression of the Hodgkin's disease-associated an- 
tigen Ki-1 in reactive and neoplastic lymphoid tissue. Evidence 
that Reed-Steruberg cells and histiocytic malignancies are de- 
rived from activated lymphoid cells. Blood. 66:848. 
3.  Froese, P., H. Lemke,  J. Gerdes, B. Havsteen, K. Schwarting, 
H. Hansen and H. Stein. 1987. Biochemical characterization 
and biosynthesis of the Ki-1 antigen in Hodgkin-derived and 
virus-transformed human B and T lymphoid cell lines.J. Im- 
munol.  139:2081. 
4.  Schwarting, R., J. Gerdes, H. Durkop, B. Falini, S. Pileri, and 
H. Stein. 1989. Bet-H2: a new anti-Ki-1 (CD30) monoclonal 
antibody directed at a formol-resistant epitope. Blood. 74:1678. 
5.  Andreesen, R., J. Osterholz, G.W. Lohr, and K.J. Bross. 1984. 
A Hodgkin's cell specific antigen is expressed on a subset of 
auto and alloreactive T (helper) lymphocytes. Blood. 63:1299. 
6.  Durkop,  H., U. Latza, M. Hummel, F. Eitelbach, B. Seed, 
and H. Stein. 1992. Molecular cloning and expression  of a new 
member of the nerve growth factor receptor family that is char- 
acteristic of Hodgkin's  disease. Cell. 68:421. 
7.  Smith, C., K. Grabstein, T. Davis, B. Gliniak, I. McAlister, 
D. Anderson, S. Gimpel, D. Williams, R. Armitage, and R.G. 
Goodwin. 1992. Molecular cloning and characterization of a 
ligand for the CD30 antigen. Blood. 80:150. 
8.  Smith, C., H.J. Gruss, T. Davis, D. Anderson, T. Farrah, E. 
Baker, G.R. Sutherland, C.I. Brannan, N.G. Copeland, N.A. 
Jenkins, et al. 1993. CD30 antigen,  a marker for Hodgkin's 
lymphoma,  is a receptor whose ligand defines an emerging 
family of cytokines with homology to TNF. Cell.  73:1349. 
9.  Del Prete, G.F., M. De Carli, F. Almerigogna, C.K. Daniel, 
M.M. D'Elios, G. Zancuoghi, G. Pizzolo, and S. Romagnani. 
Preferential expression of CD30 by human  CD4 + T  cells 
producing Th2-type cytokines.  FASEB (Fed. Am. Soa Ext~ Biol.) 
J.  In press. 
10.  Maggi, E., M.-G. Giudizi, R. Biagiotti,  F: Annunziato,  K. 
Manetti, M.-P. Piccinni, P. Parronchi, S. Sampognaro, L. Gian- 
narini, G. Zuccati, and S. Romagnani.  1994. Th2-1ike CD8 + 
T cells showing B cell helper function and reduced cytolytic 
activity in human immunodeficiency virus type 1 infection. 
J. Ex  F  Med.  180:489. 
11.  Centers for Disease Control and Prevention. 1987. Revision 
of the  CDC  surveillance case definition  for acquired im- 
munodeficiency  syndrome. MMWR (Moth Mortal. Wkly. Rel~  ). 
35:334. 
12.  Pizzolo, G., F. Vinante, L. Morosato, G. Nadali, M. Chilosi, 
G. Gandini, A. Sinicco, R. Raiteri, G. Semenzato, H. Stein, 
and G. Perona. 1994. High serum levels of the soluble form 
of CD30 molecule in the early phase of HIV-1 infection as 
an independent predictor of  progression to AIDS. AIDS. 8:741. 
13.  Yssel, H., R. de Waal Malefyt, M.-G. Roncarolo, J.S. Abrams, 
R. Lahesmaa, H. Spits, and J.E. de Vries. 1992. IL-IO is pro- 
duced by subsets of human CD4 + T cell clones and periph- 
eral blood T cells. J. Immunol.  149:2378. 
14.  Del Prete, G.-F., M. De Carli, F. Almerigogna, M.-G. Gin- 
dizi, R. Biagiotti, and S. Romagnani.  1993. Human I1.,10 is 
produced by both type 1 helper (Thl) and type 2 helper (Th2) 
T cell clones and inhibits their antigen-specific proliferation 
and cytokine production. J. Immunol.  150:353. 
15.  Fiorentino, D.F., M.W. Bond, and T.R. Mosmann. 1989. Two 
types of mouse T helper cells. IV. Th2 clones secrete a factor 
that inhibits cytokine production by Thl clones.J. Ex  F Med. 
170:2081. 
2411  Manetti  et al.  Brief  Definitive Report 